GAIN THERAPEUTICS INC (GANX) Stock News

USA - Nasdaq - NASDAQ:GANX - US36269B1052 - Common Stock

4.05 USD

+0.06 (+1.5%)

Last: 12/9/2025, 8:03:04 PM

4.0008 USD

-0.05 (-1.21%)

After Hours: 12/9/2025, 8:03:04 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

GANX Latest News, Press Relases and Analysis

All

Press Releases

2 days ago - By: Zacks Investment Research

Here's Why Gain Therapeutics, Inc. (GANX) is a Great Momentum Stock to Buy

20 days ago - By: Gain Therapeutics, Inc.

Gain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2025

23 days ago - By: Zacks Investment Research

Gain Therapeutics (GANX) Upgraded to Buy: Here's What You Should Know

a month ago - By: Gain Therapeutics, Inc.

Gain Therapeutics Reports Financial Results for Third Quarter 2025 and Provides Corporate Update

a month ago - By: Gain Therapeutics, Inc.

Gain Therapeutics Reports Financial Results for Third Quarter 2025 and Provides Corporate Update

a month ago - By: Gain Therapeutics, Inc.

Gain Therapeutics to Present at Neuroscience 2025

2 months ago - By: Gain Therapeutics, Inc.

Gain Therapeutics to Attend the 2025 Maxim Growth Summit

2 months ago - By: Gain Therapeutics, Inc.

Gain Therapeutics to Attend the 2025 Maxim Growth Summit

2 months ago - By: Gain Therapeutics, Inc.

Gain Therapeutics to Host Virtual KOL Event on GT-02287 for Parkinson’s Disease

2 months ago - By: Gain Therapeutics, Inc.

Gain Therapeutics to Host Virtual KOL Event on GT-02287 for Parkinson’s Disease

2 months ago - By: Gain Therapeutics, Inc.

Gain Therapeutics Presents Initial Data from Phase 1b Clinical Study of GT-02287 in Parkinson’s Patients at International Congress of Parkinson’s Disease and Movement Disorders®

2 months ago - By: Gain Therapeutics, Inc.

Gain Therapeutics Presents Initial Data from Phase 1b Clinical Study of GT-02287 in Parkinson’s Patients at International Congress of Parkinson’s Disease and Movement Disorders®

3 months ago - By: Gain Therapeutics, Inc.

Gain Therapeutics to Participate at Drug Discovery Innovation Programme 2025

3 months ago - By: Gain Therapeutics, Inc.

Gain Therapeutics to Participate at Drug Discovery Innovation Programme 2025

3 months ago - By: Gain Therapeutics, Inc.

Gain Therapeutics Begins Its GT-02287 Phase 1b Extension Study in People with Parkinson’s Disease

3 months ago - By: Gain Therapeutics, Inc.

Gain Therapeutics Begins Its GT-02287 Phase 1b Extension Study in People with Parkinson’s Disease

3 months ago - By: Gain Therapeutics, Inc.

Gain Therapeutics Receives Australian Approval of Phase 1b Dosing Extension and Reports Positive Independent Data Monitoring Committee Recommendation

4 months ago - By: Gain Therapeutics, Inc.

Gain Therapeutics Reports Financial Results for Second Quarter 2025 and Provides Corporate Update

4 months ago - By: Gain Therapeutics, Inc.

Gain Therapeutics Reports Financial Results for Second Quarter 2025 and Provides Corporate Update

4 months ago - By: Benzinga - Mentions: XTLB ASMB MCRB SNES ...

12 Health Care Stocks Moving In Friday's After-Market Session

5 months ago - By: Gain Therapeutics, Inc.

Gain Therapeutics to Present at BTIG Annual Virtual Biotechnology Conference

5 months ago - By: Gain Therapeutics, Inc.

Gain Therapeutics to Present at BTIG Annual Virtual Biotechnology Conference

5 months ago - By: Gain Therapeutics, Inc.

Gain Therapeutics Announces Pricing of $7.0 Million Public Offering

5 months ago - By: Gain Therapeutics, Inc.

Gain Therapeutics Announces Pricing of $7.0 Million Public Offering

5 months ago - By: Benzinga - Mentions: CYCC LIXT CBIO RPTX ...

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

5 months ago - By: Gain Therapeutics, Inc.

Gain Therapeutics Announces Proposed Public Offering

5 months ago - By: Gain Therapeutics, Inc.

Gain Therapeutics Announces Proposed Public Offering

5 months ago - By: Gain Therapeutics, Inc.

Gain Therapeutics Announces Completion of Target Enrollment in Phase 1b Clinical Study Evaluating GT-02287 in People With Parkinson’s Disease With or Without a GBA1 Mutation

5 months ago - By: Gain Therapeutics, Inc.

Gain Therapeutics Announces Completion of Target Enrollment in Phase 1b Clinical Study Evaluating GT-02287 in People With Parkinson’s Disease With or Without a GBA1 Mutation

6 months ago - By: Gain Therapeutics, Inc.

Gain Therapeutics to Participate in Upcoming Investor Conferences

6 months ago - By: Gain Therapeutics, Inc.

Gain Therapeutics Announces Oral Presentation at 2nd GBA1 Meeting

6 months ago - By: Gain Therapeutics, Inc.

Gain Therapeutics Announces Oral Presentation at 2nd GBA1 Meeting

7 months ago - By: Gain Therapeutics, Inc.

Gain Therapeutics Reports Financial Results for First Quarter 2025 and Provides Corporate Update

7 months ago - By: Gain Therapeutics, Inc.

Gain Therapeutics Reports Financial Results for First Quarter 2025 and Provides Corporate Update

7 months ago - By: Gain Therapeutics, Inc.

Gain Therapeutics Presents Preclinical Data at IAPRD 2025 30th World Congress on Parkinson’s Disease and Related Disorders

7 months ago - By: Gain Therapeutics, Inc.

Gain Therapeutics Presents Preclinical Data at IAPRD 2025 30th World Congress on Parkinson’s Disease and Related Disorders